Previous research suggests the FDA’s approval of a drug does not necessarily ensure that a drug has a large or important benefit or that all serious adverse effects of the drug are known. Uncertainties about a drug are greatest in the first few years after approval and for drugs approved solely on the basis of a surrogate outcome, researchers said.
In an Internet-based, randomized, controlled trial of nearly 3,000 participants, researchers found 25 percent of participants mistakenly believed the FDA approves only drugs without serious side effects. Results also showed more than one-third mistakenly believed that the FDA approves only “extremely effective” drugs.
Researchers recommended that physicians provide a brief and simple explanation about the known benefits and harms of a drug and that the FDA more effectively communicate what it knows and does not know about a drug’s effectiveness.
Related Articles on Medication Safety:
Study: Medication Study Results May Be Misleading
Johns Hopkins Research Suggests Temporary ED Personnel May Increase Risk of Patient Harm
Study: Discharged ICU Patients at Increased Risk of Unintentionally Discontinuing Medication
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
